Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT01914484
Title Phase I/II Study of Nilotinib/Ruxolitinb Therapy for TKI Resistant Ph-Leukemia
Recruitment Completed
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto|Novartis
Indications
Therapies
Age Groups: adult
Covered Countries CAN


No variant requirements are available.